Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
Christina E. DeRemer, Scott Martin Vouri, Jingchuan Guo, William T. Donahoo, Almut G. Winterstein, Hui Shao
Topics & Concepts
MedicineMetforminType 2 diabetesHazard ratioProportional hazards modelInternal medicineDiabetes mellitusCohortClinical endpointLower riskStroke (engine)InsulinEndocrinologyConfidence intervalClinical trialMechanical engineeringEngineeringDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes